Last A$0.10 AUD
Change Today -0.001 / -1.01%
Volume 68.7K
PXS On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 6:56 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

pharmaxis ltd (PXS) Snapshot

Open
A$0.10
Previous Close
A$0.10
Day High
A$0.10
Day Low
A$0.10
52 Week High
12/29/14 - A$0.21
52 Week Low
10/30/14 - A$0.04
Market Cap
30.4M
Average Volume 10 Days
1.9M
EPS TTM
A$-0.17
Shares Outstanding
310.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMAXIS LTD (PXS)

Related News

No related news articles were found.

pharmaxis ltd (PXS) Related Businessweek News

No Related Businessweek News Found

pharmaxis ltd (PXS) Details

Pharmaxis Ltd, a specialty pharmaceutical company, is engaged in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory and other chronic diseases worldwide. The company’s lead product and product candidates are used for the diagnosis and treatment of chronic respiratory diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), including bronchiectasis and chronic bronchitis, and other chronic and acute pulmonary conditions. It offers Aridol lung function test, which is designed to assist physicians in the assessment of asthma by identifying and measuring airway hyperresponsiveness; and Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. The company’s early product development pipeline includes orbital dry powder inhaler that delivers drug doses to the lungs; Lysyl Oxidase Like 2 (LOXL-2) inhibitors for the treatment of fibrosis; PXS-4728A–novel semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 inhibitor for the treatment of chronic lung inflammation; PXS64/25 targeting lung fibrosis; ASM8 targeting severe asthma; and PXS TPI1100 for the treatment candidate for COPD. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

107 Employees
Last Reported Date: 08/28/14
Founded in 1998

pharmaxis ltd (PXS) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: A$453.3K
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: A$363.9K
Chief Medical Officer and Member of Disclosur...
Total Annual Compensation: A$349.6K
Head of Drug Discovery
Total Annual Compensation: A$240.3K
Head of Regulatory Affairs
Total Annual Compensation: A$237.0K
Compensation as of Fiscal Year 2014.

pharmaxis ltd (PXS) Key Developments

Pharmaxis Ltd., Annual General Meeting, Nov 27, 2014

Pharmaxis Ltd., Annual General Meeting, Nov 27, 2014., at 14:30 AUS Eastern Standard Time. Location: Christie Conference Centre.

Pharmaxis Ltd. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended June 30, 2014

Pharmaxis Ltd. reported unaudited earnings results for the fourth quarter and year ended June 30, 2014. For the quarter, the company reported revenue from sale of goods of AUD 1,441,000 against AUD 962,000 a year ago. Interest income was AUD 340,000 against AUD 708,000 a year ago. Net loss before tax was AUD 20,957,000 against AUD 12,941,000 a year ago. Net loss after tax was AUD 20,951,000 or AUD 0.068 per basic and diluted share against AUD 12,878,000 or AUD 0.042 per basic and diluted share a year ago. For the year, the company reported revenue from sale of goods of AUD 5,036,000 against AUD 3,237,000 a year ago. Interest income was AUD 1,735,000 against AUD 2,695,000 a year ago. Net loss before tax was AUD 51,715,000 against AUD 42,721,000 a year ago. Net loss after tax was AUD 51,818,000 or AUD 0.168 per basic and diluted share against AUD 42,723,000 or AUD 0.141 per basic and diluted share a year ago.

Pharmaxis Ltd.(ASX:PXS) dropped from S&P/ASX All Ordinaries Index

Pharmaxis Ltd.(ASX:PXS) dropped from S&P/ASX All Ordinaries Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PXS:AU A$0.10 AUD -0.001

PXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PXS.
View Industry Companies
 

Industry Analysis

PXS

Industry Average

Valuation PXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.0x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAXIS LTD, please visit www.pharmaxis.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.